Has Jeffrey Fischer, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,314 in general payments to Jeffrey Fischer, MD across 77 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Fischer, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Fischer, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Fischer, MD

Ophthalmology · Willmar, MNNPI 1386693604

Payments from drug & device makers

What this record shows

15 manufacturers reported payments, led by Alcon at 56.0% of the total. Reporting peaked in 2019 at $3,318 and has fallen 89.0% since, to $365 in 2025.

$4,314in general payments, 2019–2025

Across 77 payments — averaging $56.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$2K
Johnson & Johnson Surgical Vision, Inc.$1K
The Cameron-ehlen Group, Inc.$190
Sight Sciences, Inc.$113
Biotissue Holdings Inc.$65
Carl Zeiss Meditec, Inc.$65
plus $323 from 9 others

$502,245in research payments, 2019–2025

Across 231 payments — averaging $2174.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Carl Zeiss Meditec, Inc.$319K
Alcon Research LLC$183K

What the payments were for

Travel & lodging$2,03447%
Food & beverage$2,28053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	41	$2,415
Johnson & Johnson Surgical Vision, Inc.	5	$1,144
The Cameron-ehlen Group, Inc.	4	$190
Sight Sciences, Inc.	3	$113
Biotissue Holdings Inc.	3	$65
Carl Zeiss Meditec, Inc.	1	$65
Glaukos Corporation	2	$61
Ocular Therapeutix, Inc.	3	$48
Omeros Corporation	3	$40
Rayner Intraocular Lenses Limited	2	$31
Lensar, Inc.	2	$30
Oyster Point Pharma, Inc.	2	$30
AbbVie(2 entities)	2	$29
Dompe US, Inc.	2	$27
Rxsight Inc	2	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Tecnis 1-piece IOL$1,024
Tecnis Multifocal Family of 1-piece IOLS$1,024
Tecnis Symfony IOL$1,024
AcrySof$321

How this compares

$4,314 in reported general payments places this provider in the 85th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$315,317

Medicare patients

395

Services billed

1,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	365	$11,985
Ketorolac Tromethamine	64	$2,720
Fluorometholone	15	$1,023
Ofloxacin	70	$901
ValacyclovirValacyclovir Hcl	18	$586
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	13	$261
Latanoprost	25	$242
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	12	$91

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Willmar

Edwin RyanMinneapolis$9.6M
Mark LobanoffSt Louis Park$6.3M
Richard LindstromBloomington$5.6M
Thomas SamuelsonMinnetonka$435K
Deborah RistvedtAlexandria$392K
Yun-Sen ChuBloomington$222K
Sophie BakriRochester$183K
David HardtenMinneapolis$119K
John ChenRochester$82K
Christine LarsenBloomington$70K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →